Is GHK-Cu FDA-approved for hair loss?

No. The FDA has not approved GHK-Cu for hair loss or any form of alopecia. The compounded 1% scalp solution and the GHK-Cu creams and serums are prepared under section 503A to an individual prescription and have not been evaluated by the FDA. Injectable GHK-Cu carries a separate FDA entry: placed in category 2 of the 503A bulk substances policy, with the nomination withdrawn in April 2026.

What did the follicle organ-culture study on copper peptides actually use?

The 2007 study by Pyo and colleagues in Archives of Pharmacal Research used AHK-Cu, alanyl-histidyl-lysine complexed with copper, a structural relative of GHK-Cu. It reported follicle elongation and dermal papilla cell proliferation in organ culture. The finding is relevant to copper peptides as a class and is not a finding about GHK-Cu itself.

Has GHK-Cu been tested in a human hair loss trial?

No randomised controlled trial of GHK-Cu in human pattern hair loss has been published as of this review. The hair-specific evidence is organ culture with a related peptide and a 1993 primate model of copper-binding peptides. The human GHK-Cu literature is concentrated in skin, cosmetic formulations and wound studies.

What does the FDA entry for GHK-Cu say, and does it cover the scalp solution?

The FDA entry is expressly for GHK-Cu for injectable routes of administration: FDA placed it in category 2 and the nomination was withdrawn in April 2026, and the agency’s rationale concerns immunogenicity risk from aggregation and peptide-related impurities in injectable preparations. The topical scalp solution is prepared by our 503A pharmacy partner, licensed by the Texas State Board of Pharmacy, against an individual prescription, and the basis on which the pharmacy compounds it is the pharmacy’s determination under that board’s oversight. ExaVeyra does not supply GHK-Cu as an injectable or as a bulk research substance.

Where is the wider GHK-Cu literature covered?

The peptide evidence page at /science/peptides/ghk-cu covers the molecule’s chemistry, the gene-expression and wound literature summarised in the 2018 review by Pickart and Margolina, and the FDA’s position on the injectable form in detail. This page confines itself to the follicle and dermal papilla research.

Hair and scalp evidence

GHK-Cu in Follicle and Dermal Papilla Research

Reviewed by ExaVeyra Sciences editorial team · Updated 15 September 2026

ExaVeyra Sciences is a Miami-based B2B supplier of research-use exosomes to licensed clinics, and it refers licensed prescribers to a 503A compounding pharmacy that prepares formulations against individual prescriptions.

What this page covers, who can buy from ExaVeyra, and what is supplied
Question	Answer
What this is	What the copper tripeptide literature reports in follicle organ culture and animal models, which peptide each study used, and the regulatory position.
Who can buy	Licensed clinics and practitioners, after ExaVeyra verifies an active professional license and NPI and, for exosome material, a signed research-use acknowledgment.
What ships or is provided	Research-use exosome formats and PRP devices ship from ExaVeyra through one verified account; compounded formulations are prepared and dispensed by our 503A pharmacy partner against a patient-specific prescription and do not ship from ExaVeyra. A certificate of analysis is issued for every lot and provided on request.

GHK-Cu is the tripeptide glycyl-histidyl-lysine complexed with copper, a naturally occurring sequence first isolated from human plasma in the 1970s. The FDA has not approved GHK-Cu for hair loss or any form of alopecia, no randomised trial of GHK-Cu in human pattern hair loss has been published, and the follicle study most often cited for copper peptides used a structural relative rather than GHK-Cu itself. This page reports what the literature does contain, in follicle organ culture, in an animal model and in the review literature, and states the regulatory position of the compounded scalp solution and of injectable GHK-Cu, which differ.

It is an evidence reference. The compounded hair and scalp formulations page on this site lists the 1% GHK-Cu scalp solution the 503A pharmacy partner can prepare, and the skin and aesthetics page lists the GHK-Cu creams and serums; neither says what any of them does, and neither does this page.

What the molecule is, and where its literature comes from

GHK binds copper(II) with high affinity, and most of what is written about it concerns the copper complex. The 2018 review by Pickart and Margolina in the International Journal of Molecular Sciences summarised the literature that had accumulated since the 1970s: gene-expression studies reporting changes across large sets of human genes, and in vitro and animal work described in the context of wound models, collagen and glycosaminoglycan synthesis, angiogenesis, and anti-inflammatory signalling. The review is the standard entry point to the field and is cited here as such.

Most of that literature is about skin and wounds rather than hair. The peptide evidence page at /science/peptides/ghk-cu covers the molecule’s chemistry, the breadth of that literature and the FDA’s position on the injectable form; this page confines itself to the follicle.

The follicle organ-culture study, and which peptide it used

The study most often cited for copper peptides and hair is Pyo and colleagues, published in Archives of Pharmacal Research in 2007. Using human hair follicles in organ culture and cultured dermal papilla cells, the authors reported that a tripeptide-copper complex elongated the follicles, increased dermal papilla cell proliferation, and reduced markers of programmed cell death in those cells at picomolar to nanomolar concentrations.

The peptide in that study was AHK-Cu, alanyl-histidyl-lysine complexed with copper, a structural relative of GHK-Cu that differs in its first residue. The two peptides share a copper-binding motif and are often discussed together, and the finding is genuinely relevant to the class. It is not a finding about GHK-Cu, and a page that cited it as one would be substituting one molecule for another in the way the TB-500 evidence page on this site describes for thymosin beta-4.

The animal model

Uno and Kurata reported in a 1993 supplement of the Journal of Investigative Dermatology on chemical agents and peptides that affect hair growth, including copper-binding peptides studied in a macaque model of androgenetic alopecia. The report described follicle enlargement in that model. It is a primate study from the early 1990s, it studied copper-binding peptides as a class, and it has not been followed by a controlled human trial of GHK-Cu for hair.

What the human evidence does not yet contain

No randomised controlled trial of GHK-Cu in human pattern hair loss has been published. The human literature on GHK-Cu is concentrated in skin, in cosmetic formulations and in wound studies, and the hair literature is organ culture and animal work. That is the state of the field as of this review, and it is stated once here rather than hedged in every sentence.

Organ culture: human follicles and dermal papilla cells, with a tripeptide-copper complex (AHK-Cu) in the 2007 study.
Animal model: copper-binding peptides in a macaque model, reported in 1993.
Reviews: the 2018 review summarises gene-expression, wound and skin literature; hair is a minor part of it.
Human trials in pattern hair loss: none published for GHK-Cu.

Regulatory position: the scalp solution and the injectable differ

No GHK-Cu product is FDA-approved for any hair indication. The 1% scalp solution and the GHK-Cu creams and serums are compounded preparations, prepared by our 503A pharmacy partner, licensed by the Texas State Board of Pharmacy, against an individual prescription and under that board’s oversight, and not evaluated by the FDA for safety, effectiveness or quality. Cosmetic-grade copper peptide products marketed without disease claims sit in a separate regulatory lane again.

Injectable GHK-Cu is different. FDA placed GHK-Cu for injectable routes of administration in category 2 of its interim policy on bulk drug substances for compounding under section 503A, meaning the agency identified significant safety risks, and the nomination was withdrawn by the nominator in April 2026. FDA now carries the substance under nominations withdrawn and still publishes the rationale it wrote, and a withdrawn nomination leaves the substance on no 503A list for any route. The entry is written for injectable routes, and what it does or does not establish for a topical preparation is a determination for the compounding pharmacy under its state board’s oversight, which this page does not make. The FDA’s stated rationale for the injectable entry is reproduced here in full:

ExaVeyra does not supply GHK-Cu as an injectable or as a bulk research substance. The topical formulations the pharmacy partner prepares are listed on the product pages linked below by composition and dating only.

Sources

FDA, Compounding and the FDA: Questions and Answers (accessed 15 September 2026)
FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (accessed 16 September 2026)

Scientific literature

Each source carries the kind of study it was and, where the study enrolled people, how many. Study design decides what a result can establish, so it is stated rather than left to be inferred. Each line also says what that source is carrying on this page.

Pickart L, Margolina A Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences, 2018. doi:10.3390/ijms19071987 PMID:29986520Narrative reviewSource 1 supports: The standard review of the GHK-Cu literature, cited for the scope of the gene-expression, wound and skin work and to show how small a part of it concerns hair.
Pyo HK, Yoo HG, Won CH, et al. The effect of tripeptide-copper complex on human hair growth in vitro. Archives of Pharmacal Research, 2007. doi:10.1007/BF02978833 PMID:17703734In vitroSource 2 supports: The follicle organ-culture study, cited for its dermal papilla and follicle elongation findings and for the fact that the peptide studied was AHK-Cu rather than GHK-Cu.
Uno H, Kurata S Chemical agents and peptides affect hair growth. Journal of Investigative Dermatology, 1993. PMID:8326148PreclinicalSource 3 supports: The primate model report on copper-binding peptides, cited as the animal evidence and dated so a reader can see that it has not been followed by a human trial.
Pickart L, Vasquez-Soltero JM, Margolina A GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. BioMed Research International, 2015. doi:10.1155/2015/648108 PMID:26236730Narrative reviewSource 4 supports: The earlier review, cited for the plasma-decline observation and its summary of the cosmetic-formulation studies in human skin.
Mokhtar J, Mohamad B, Haddad J, et al. The regenerative potential of GHK-Cu in aesthetic medicine. Aesthetic Surgery Journal, 2026. doi:10.1093/asj/sjag169 PMID:42619529Narrative reviewSource 5 supports: The most recent review of GHK-Cu in aesthetic practice, cited for how the field currently frames the peptide and for its account of the hair evidence.
Campbell JD, McDonough JE, Zeskind JE, et al. A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. Genome Medicine, 2012. doi:10.1186/gm367 PMID:22937864In vitroSource 6 supports: The gene-expression study that underlies the claim of broad transcriptional effects, cited so a reader can see it was a lung-tissue signature study rather than a hair study.
Journal of Orthopaedic Research, 2015 Tripeptide-copper complex GHK-Cu(II) transiently improved healing outcome in a rat model of ACL reconstruction. Journal of Orthopaedic Research, 2015. doi:10.1002/jor.22831 PMID:25731775PreclinicalSource 7 supports: An animal model in which GHK-Cu itself was studied and a transient outcome reported, cited as representative of the preclinical literature.
Otolaryngology, Head and Neck Surgery, 2013 Effects of topical copper tripeptide complex on wound healing in an irradiated rat model. Otolaryngology, Head and Neck Surgery, 2013. doi:10.1177/0194599813492644 PMID:23744835PreclinicalSource 8 supports: The irradiated-wound rat model, cited for the topical route and for the design most of the wound literature shares.
Pharmaceutical Research, 2015 Microneedle-mediated delivery of copper peptide through skin. Pharmaceutical Research, 2015. doi:10.1007/s11095-015-1652-z PMID:25690343In vitroSource 9 supports: The delivery study, cited for why copper peptide formulations are paired with microneedling in practice.
Ogorek K, Nowak K, Wadych E, et al. Are we ready to measure skin permeation of modern antiaging GHK-Cu tripeptide encapsulated in liposomes?. Molecules, 2025. doi:10.3390/molecules30010136 PMID:39795193Narrative reviewSource 10 supports: A 2025 review of permeation methods for liposomal GHK-Cu, cited for the delivery question that governs any topical scalp formulation.
Hu J, Zhang C, Wang F, et al. Glycyl-L-histidyl-L-lysine-Cu2+ (GHK-Cu) attenuates CuSO4 or LPS induced-inflammation in zebrafish larvae model. European Journal of Pharmacology, 2026. doi:10.1016/j.ejphar.2026.178880 PMID:41997403PreclinicalSource 11 supports: A 2026 zebrafish inflammation model, cited as the most recent preclinical work on the anti-inflammatory signalling the reviews describe.

Apply for wholesale access Ask our team

Common questions

Is GHK-Cu FDA-approved for hair loss?: No. The FDA has not approved GHK-Cu for hair loss or any form of alopecia. The compounded 1% scalp solution and the GHK-Cu creams and serums are prepared under section 503A to an individual prescription and have not been evaluated by the FDA. Injectable GHK-Cu carries a separate FDA entry: placed in category 2 of the 503A bulk substances policy, with the nomination withdrawn in April 2026.
What did the follicle organ-culture study on copper peptides actually use?: The 2007 study by Pyo and colleagues in Archives of Pharmacal Research used AHK-Cu, alanyl-histidyl-lysine complexed with copper, a structural relative of GHK-Cu. It reported follicle elongation and dermal papilla cell proliferation in organ culture. The finding is relevant to copper peptides as a class and is not a finding about GHK-Cu itself.
Has GHK-Cu been tested in a human hair loss trial?: No randomised controlled trial of GHK-Cu in human pattern hair loss has been published as of this review. The hair-specific evidence is organ culture with a related peptide and a 1993 primate model of copper-binding peptides. The human GHK-Cu literature is concentrated in skin, cosmetic formulations and wound studies.
What does the FDA entry for GHK-Cu say, and does it cover the scalp solution?: The FDA entry is expressly for GHK-Cu for injectable routes of administration: FDA placed it in category 2 and the nomination was withdrawn in April 2026, and the agency’s rationale concerns immunogenicity risk from aggregation and peptide-related impurities in injectable preparations. The topical scalp solution is prepared by our 503A pharmacy partner, licensed by the Texas State Board of Pharmacy, against an individual prescription, and the basis on which the pharmacy compounds it is the pharmacy’s determination under that board’s oversight. ExaVeyra does not supply GHK-Cu as an injectable or as a bulk research substance.
Where is the wider GHK-Cu literature covered?: The peptide evidence page at /science/peptides/ghk-cu covers the molecule’s chemistry, the gene-expression and wound literature summarised in the 2018 review by Pickart and Margolina, and the FDA’s position on the injectable form in detail. This page confines itself to the follicle and dermal papilla research.

Reference only. Not legal or medical advice.

The content of these guides is provided for general informational purposes only. It does not constitute legal, medical, or regulatory advice, and does not establish that any particular product or practice is compliant. Regulatory requirements vary by state and depend on the circumstances of each practice. Each practitioner should consult their own legal counsel and the applicable state licensing boards before acting on anything stated here.

Read the full disclaimer

ExaVeyra Sciences publishes these guides as a reference for licensed practitioners. They summarize publicly available federal and state requirements as those requirements read on the review date shown above. The content is provided for general informational purposes only and does not constitute legal, medical, or regulatory advice, and it does not establish that any particular product or practice is compliant.

No attorney-client relationship, and no professional or clinical relationship of any kind, is created by accessing these materials. ExaVeyra Sciences is a supplier of research-use materials. It is not a law firm, it is not a regulatory consultant, and it takes no part in any diagnosis, treatment decision, or plan of care. Each practitioner is responsible for retaining their own legal counsel and for determining, with that counsel and the applicable state licensing boards, how the requirements described here apply to the services, staffing, and structure of their own practice.

Statutes, regulations, board rules, and agency positions are subject to amendment, supersession, and reinterpretation. ExaVeyra Sciences makes no representation or warranty as to the accuracy, completeness, timeliness, or applicability of this content to any particular practice. Citations and links to third-party sources are provided for convenience only and do not constitute an endorsement of their content.

The practitioner and the practice are solely responsible for compliance with all applicable licensing, scope of practice, supervision, ownership, facility, recordkeeping, and tax requirements, and for all clinical decisions, including the suitability of any material for a given patient. To the fullest extent permitted by law, ExaVeyra Sciences disclaims all liability for any action taken or not taken in reliance on this content.